OSUR

OraSureC

Nasdaq / Health Care Equipment & Services

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$4.75

+17.9% vs current

Most likely

Base case

50%

Probability

Target price

$3.40

-15.6% vs current

B-

Bear case

25%

Probability

Target price

$2.20

-45.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This is a cautious T+3 post-earnings update. Primary company sources are strong and show a mixed print on May 6, 2026: revenue landed above the midpoint of guidance and margin improved, but losses and burn stayed heavy. Market reaction also looks muted rather than thesis-changing: the packet anchor was $3.13 on May 7, 2026, and live price data on May 8, 2026 showed OSUR around $3.06, a low-single-digit move lower after the release. I did not find a reliable post-print analyst revision set from checked sources, so the memo stays monitoring-oriented rather than upgraded.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06catalystPost-earnings setup is now about proving Q2 stability rather than just clearing a low barHigh impact

Q1 revenue of $27.9 million came in above the midpoint of management's prior guidance, core revenue was down only 0.5% year over year, and gross margin improved to 42.3%, but operating loss still widened to $23.3 million. Q2 guidance of $27 million to $30 million keeps the near-term bar centered on holding revenue and margin gains while limiting further burn. [#8-K-2026-05-06] [#10-Q-2026-05-08]

2026-12-31eventFDA review outcomes for Colli-Pee and the Sherlock CT/NG self-test remain the cleanest upside triggerHigh impact

Management's May 2026 investor update says regulatory review is underway for both the Colli-Pee at-home first-void urine self-collection device and the disposable rapid molecular CT/NG self-test following FDA submissions in December 2025. With current core revenue still only stable at a low base, favorable review progress or launch timing would be the clearest path to a sentiment upgrade. [#8-K-2026-05-06]

2026-12-31catalystBalance-sheet support buys time, but rerating still needs core breakeven progressHigh impact

OraSure ended March 31, 2026 with $177.0 million of cash and cash equivalents, and management highlighted a no-debt balance sheet, but Q1 still used $13.9 million of operating cash and the company posted a $22.4 million net loss. The long case depends less on cash alone and more on turning manufacturing efficiencies and new-product launches into a credible path toward breakeven and margin expansion. [#10-Q-2026-05-08] [#8-K-2026-05-06]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology